Buy & Sell Halliburton Company (HAL) – Halliburton Company Price Today
Aura AI Summary
Key Stats
- $31.90BMarket Cap
- EnergySector
- -11.17%3M Drawdown
- $37.97BEnterprise Value
- 1.78%Dividend Yield
- 26% Buy | 74% SellTrading Activity
- 85 daysTypical Hold Time
Halliburton Company (HAL) is currently valued at a market capitalization of $31.90B, with an enterprise value of $37.97B. Over the past 52 weeks, Halliburton Company has traded between a low of $20.26 and a high of $42.98, highlighting its annual price range. Over the past three months, Halliburton Company has recorded a drawdown of -11.17%, reflecting recent price volatility. Halliburton Company offers a dividend yield of 1.78%, with the most recent dividend of $0.17 paid on 03 Jun 26. On average, investors hold Halliburton Company for approximately 85 days, indicating typical investor behavior on the platform.
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Most Recent News
Capital Link Shipping launches new CEO insights on tanker markets, maritime resilience, and capital markets.
Capital Link Shipping has expanded its Maritime Intelligence Hub with new executive insights from leaders at Scorpio Tankers, DHT Holdings, d’Amico International Shipping, and others. These discussions cover market trends in crude oil and product tan...

Centene offers voluntary staff buyouts amid major ACA membership drop
Centene, a major U.S. health insurer, has launched a voluntary separation program allowing eligible employees to apply for buyouts as it faces a significant decline in membership, especially in its Affordable Care Act (ACA) marketplace plans. Members...

US agency proposes broader Medicare coverage for heart valve device, boosting Edwards Lifesciences.
The US Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) in patients with symptomatic severe aortic stenosis. CMS also suggested...
